June 27th 2022
Nilanjan Ghosh, MD, PhD, discusses the low toxicity levels with lisocabtagene maraleucel that were seen in patients with relapsed/refractory large B cell lymphoma in the phase 3 TRANSFORM trial.
April 5th 2021
Nilanjan Ghosh, MD, PhD, discusses the potential advantages of moving CAR T-cell therapy into the frontline setting for patients with diffuse large B-cell lymphoma.
December 1st 2020
Nilanjan Ghosh, MD, PhD, director of the Lymphoma Program and a physician with Levine Cancer Institute, discusses unmet needs with CAR T-cell therapy in diffuse large B-cell lymphoma.
September 14th 2020
Nilanjan Ghosh, MD, PhD, discusses approved BTK inhibitors in B-cell malignancies.
September 10th 2020
Nilanjan Ghosh, MD, PhD, discusses remaining questions with BTK inhibitors in chronic lymphocytic leukemia and small lymphocytic lymphoma.
August 18th 2020
Nilanjan Ghosh, MD, PhD, compares different BTK inhibitors in B-cell malignancies.
August 14th 2020
Nilanjan Ghosh, MD, PhD, discusses global trials examining zanubrutinib in mantle cell lymphoma and non-Hodgkin lymphoma.
August 12th 2020
Nilanjan Ghosh, MD, PhD, discusses the role of minimal residual disease in chronic lymphocytic leukemia.
July 31st 2020
Nilanjan Ghosh, MD, PhD, discusses the utility of lisocabtagene maraleucel in relapsed/refractory non-Hodgkin lymphoma.
July 23rd 2020
Nilanjan Ghosh, MD, PhD, discusses the safety results from the phase 2 PILOT study with lisocabtagene maraleucel in non-Hodgkin lymphoma.
June 25th 2020
Nilanjan Ghosh, MD, PhD, discusses efficacy results from the phase 2 PILOT trial in patients with high-risk relapsed/refractory B-cell non-Hodgkin lymphoma.
June 18th 2020
Nilanjan Ghosh, MD, PhD, discusses the need to develop novel therapies in diffuse large B-cell lymphoma.
June 6th 2018
Nilanjan Ghosh, MD, PhD, physician, Levine Cancer Institute, discusses the role of bleomycin in the treatment of patients with classical Hodgkin lymphoma.
May 17th 2018
Nilanjan Ghosh, MD, PhD, physician, Levine Cancer Institute, discusses frontline immunotherapy in Hodgkin lymphoma.
May 7th 2018
Nilanjan Ghosh, MD, PhD, physician, Levine Cancer Institute, discusses the future of chimeric antigen receptor (CAR) T-cell therapy in the treatment of patients with hematologic malignancies.
April 28th 2018
Nilanjan Ghosh, MD, PhD, physician, Levine Cancer Institute, discusses PET-adapted therapy in patients with Hodgkin lymphoma.